MiMedx Group (NASDAQ: MDXG) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its competitors? We will compare MiMedx Group to similar businesses based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Risk and Volatility

MiMedx Group has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, MiMedx Group’s competitors have a beta of 1.06, suggesting that their average stock price is 6% more volatile than the S&P 500.

Valuation and Earnings

This table compares MiMedx Group and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
MiMedx Group $283.32 million $32.97 million 63.85
MiMedx Group Competitors $827.23 million $159.49 million 36.66

MiMedx Group’s competitors have higher revenue and earnings than MiMedx Group. MiMedx Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares MiMedx Group and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MiMedx Group 7.48% 15.95% 11.13%
MiMedx Group Competitors -127.09% -36.26% -10.19%

Institutional & Insider Ownership

60.4% of MiMedx Group shares are owned by institutional investors. Comparatively, 63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 12.4% of MiMedx Group shares are owned by insiders. Comparatively, 12.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for MiMedx Group and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group 1 0 3 1 2.80
MiMedx Group Competitors 164 1113 2440 88 2.64

MiMedx Group currently has a consensus target price of $16.00, indicating a potential upside of 31.90%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.21%. Given MiMedx Group’s stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than its competitors.

Summary

MiMedx Group beats its competitors on 7 of the 13 factors compared.

About MiMedx Group

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Receive News & Stock Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related stocks with our FREE daily email newsletter.